Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Exiqon A/S - Exiqon A/S completes litigation against Santaris Pharma a/s

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/07/2011 | 08:20pm CEST
Exiqon A/S
Company Announcement
Exiqon A/S completes litigation against Santaris Pharma a/s

Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced that the company has completed its litigation against Santaris Pharma a/s.

In 2010, Exiqon initiated arbitration proceedings to defend its business against Santaris Pharma.

Exiqon’s product offering includes LNA™ amidites and LNA™ oligonucleotides for the research and development of pharmaceutical products. Exiqon has the exclusive right to supply such products except for use in the research and development of pharmaceutical products containing LNA™ as the active ingredient. Today’s decision by the arbitration court establishes Exiqon’s non-exclusive right to supply these products also for the research and development of pharmaceutical products containing LNA™ as the active ingredient. Santaris Pharma’s request that Exiqon should be prevented from supplying LNA™ products for such use was dismissed.

Following today’s decision, it is clear that both Exiqon and Santaris Pharma may supply LNA™ products for the research and development of pharmaceutical products containing LNA™ as the active ingredient.

In a comment, President and CEO of Exiqon, Lars Kongsbak said: “Exiqon is committed to provide best in class products for the detection of nucleic acids using our LNA™ technology. This has allowed us to become a leader in our markets, and serves as the foundation for Exiqon’s commitment to develop, and help propel the development of, novel molecular diagnostic products, including companion diagnostics, for which we provide easy access to our proprietary technologies through licensing. Proceedings against Santaris Pharma were an unfortunate, but necessary, step towards realizing our business goals.”

Exiqon had requested that Santaris Pharma be ordered to pay damages. However, the arbitration court did not find grounds for damages.

During proceedings, Santaris Pharma submitted a counter claim against Exiqon for damages in the amount of DKK 100 million. This claim was dismissed on substantive grounds.

The arbitration court also decided on the distribution of the costs of proceedings. Santaris Pharma was awarded partial costs of DKK 2 million payable by Exiqon within 14 days.

Exiqon expect today’s decision to impact its full year EBITDA, for which guidance has been provided exclusive of one-time items, with approximately DKK -10 million.

Additional information
Lars Kongsbak, CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)

See the full press release in the attached PDF or at www.exiqon.com/investor/portal.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
02:47p SAMSUNG ELECTRONICS : Brandishes Galaxy S8 & S8+ As Best Smartphones Ever
02:47p NEW SAMSUNG GALAXY S8 : Bye, bye home button
02:47p MASTERCARD : Masterpass QR to Impact 250,000 African Merchants on Financial Empowerment
02:47p IIROC Trading Resumption - RUF.U; RUF.UN
02:47p Alta Mesa Announces Fourth Quarter & Year-End 2016 Earnings Conference Call
02:46p Canada producer prices rise in February for sixth straight month
02:46pDJU.S. Corporate Profits Rose Again in Fourth Quarter of 2016
02:46pDJU.S. Jobless Claims Fell to 258,000 Last Week
02:46p HANNAN METALS : Mineralogical Analysis for the Kilbricken Project, Ireland
02:46p DEBBIE'S DREAM FOUNDATION : Curing Stomach Cancer Hosts 8th Annual Dream Makers Gala
Latest news
Advertisement
Hot News 
-5.23%H & M HENNES & MAURITZ : &M Profit Slips as Toug Retail Conditions Dent Sales Growt
1.02%India's Mahindra Plans Electric Vehicles for U.S. and China
-2.93%Mexico's governors tap investors in China, elsewhere
-1.61%SSE : says 2017/18 dividend cover to be at lower end of guidance
8.03%GENEL ENERGY : targets Turkey gas deal this year to overcome oil troubles
Most Read News
03/29 ConocoPhillips sells oil and gas assets to Cenovus for $13.3 billion
04:54a AMERICAN INTERNATIONAL : Lloyd's of London chooses Brussels for EU base on strong regulation
02:52aDJH & M HENNES & MAURITZ : &M Profit Slips as Toug Retail Conditions Dent Sales Growt
06:38a H&M invests in supply chain as fashion rivalry intensifies
06:39a Saudi Aramco formally appoints banks to advise on share sale
Most recommended articles
03/29DJS&P 500, Nasdaq Futures -- Technical Analysis
03/27 Dollar hits four-month low as Trump trade deflates
08:45a Westinghouse wins UK reactor approval from nuclear regulator
08:35aDJWALT DISNEY : Departed Disney Executive Linked to Firm That Used Brand Without Approval
08:25a AMAZON COM : India privately took Amazon to task over insulting flag doormat